

Ipilimumab MDX010-20

PRELIMINARY SCORE

CURATIVE

NON-CURATIVE

OS

ADJUSTMENTS

Quality of life

No QoL benefit

Serious and disabling adverse effects

Other adjustments

Ipilimumab MDX010-20

SCORE

CURATIVE

Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE

4

Overall Survival

Progression-Free Survival

Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate

Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Skin Cancers  
Therapeutic Indication: Second-line treatment in advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older (pre-immunotherapy era)  
Experimental Arm: Ipilimumab  
Control Arm: Glycoprotein 100 (GP100)



